The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Lisocabtagene maraleucel (liso-cel) in patients (pt) with R/R mantle cell lymphoma (MCL): Subgroup analyses by number of prior systemic lines of therapy (LOT) and by response to prior Bruton tyrosine kinase inhibitor (BTKi) from the TRANSCEND NHL 001 MCL cohort (TRANSCEND-MCL).
 
Maria Lia Palomba
Stock and Other Ownership Interests - Notch Therapeutics (I); Pluto Immunotherapeutics (I); Seres Therapeutics (I)
Honoraria - ceramedix (I); Frazier Healthcare Partners (I); Garuda Therapeutics (I); GlaxoSmithKline (I); Lygenesis (I); Nektar (I); Notch Therapeutics (I); Pluto Immunotherapeutics (I); Rheos Medicines (I); Seres Therapeutics (I); thymofox (I)
Consulting or Advisory Role - BeiGene; bristol m; Cellectar; MustangBio; Seres Therapeutics (I); Synthekine
Research Funding - Seres Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Intellectual Property Rights (I); Juno intellectual property rights (Inst)
 
Tanya Siddiqi
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Celgene; Kite, a Gilead company
Speakers' Bureau - AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene
Research Funding - Acerta Pharma (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb/Sanofi (Inst); Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); Oncternal Therapeutics (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
 
Leo I. Gordon
Stock and Other Ownership Interests - Zylem
Consulting or Advisory Role - Bristol Meyers Squibb; Kite, a Gilead company; Ono Pharmaceutical
Patents, Royalties, Other Intellectual Property - Zylem
 
Manali Kirtikumar Kamdar
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Genentech/Roche; Syncopation Life Sciences
Speakers' Bureau - Seagen
Research Funding - Novartis
 
Matthew Alexander Lunning
Consulting or Advisory Role - Abbvie; Acrotech Biopharma; ADC Therapeutics; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; crispr therapeutics; Daiichi Sankyo/Lilly; EUSA Pharma; Fate Therapeutics; Genentech; Genmab; Instil Bio; Ipsen; Kite, a Gilead company; Loxo; Miltenyi Biotec; MorphoSys; Novartis; Nurix; Pharmacyclics; Regeneron; Sanofi; Seagen; Takeda; TG Therapeutics
Research Funding - Celgene (Inst); curis (Inst)
 
Alexandre V. Hirayama
Honoraria - Bristol-Myers Squibb/Celgene
Research Funding - Juno Therapeutics; Nektar
 
Jeremy S. Abramson
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb/Celgene; Janssen; Kite, a Gilead company; Regeneron
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Alimera Sciences; AstraZeneca; BeiGene; Bluebird Bio; Bristol-Myers Squibb; C4 Therapeutics; Caribou Biosciences; Celgene; Cellectar; Century Therapeutics; EMD Serono; Epizyme; Genmab; Incyte; Interius Biotherapeutics; Janssen; Karyopharm Therapeutics; Kite, a Gilead company; Kymera; Lilly; MorphoSys; MorphoSys; MustangBio; Novartis; Ono Pharmaceutical; Roche/Genentech; Seagen; Takeda
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Cellectis (Inst); Merck (Inst); MustangBio (Inst); Regeneron (Inst); Seagen (Inst)
 
Jon Arnason
Honoraria - Bristol-Myers Squibb/Celgene/Juno
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene/Juno
 
Nilanjan Ghosh
Consulting or Advisory Role - Abbvie/Pharmacyclics; ADC Therapeutics; AstraZeneca; Beigene; Bristol-Myers Squibb; Genmab; Incyte; Janssen Oncology; Kite, a Gilead Company; Lava Therapeutics; Loxo/Lilly; Novartis; Novartis; Roche/Genentech; Seagen; Syncopation Life Sciences
Speakers' Bureau - AstraZeneca
Research Funding - Abbvie (Inst); Bristol-Myers Squibb/Celgene (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); MorphoSys (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
 
Amitkumar Mehta
Stock and Other Ownership Interests - WITTY HEALTH
Consulting or Advisory Role - AstraZeneca; BeiGene; Gilead Sciences; Incyte; Incyte; Kyowa Kirin International; Novartis; Pharmacyclics; Roche/Genentech; Seagen; TG Therapeutics
Speakers' Bureau - Adaptive Biotechnologies; BeiGene; Epizyme; Gilead Sciences; Incyte; Kite, a Gilead company; Kyowa Kirin International; Seagen
Research Funding - ADC Therapeutics (Inst); ADC Therapeutics (Inst); Affimed Therapeutics (Inst); Aileron Therapeutics (Inst); Artiva (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Fate Therapeutics (Inst); Forty Seven (Inst); Gilead Sciences (Inst); I-Mab (Inst); incyte (Inst); Innate Pharma (Inst); Juno Therapeutics (Inst); Merck (Inst); Ono Pharmaceutical (Inst); Pharmacyclics/Janssen (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst); TG Therapeutics (Inst); TG Therapeutics (Inst)
 
Charalambos Andreadis
Consulting or Advisory Role - Atara Biotherapeutics; BMS; Epizyme; Gilead Sciences; Incyte; Karyopharm Therapeutics; Kite, a Gilead company
Research Funding - BMS; Genmab; Merck; Novartis; Roche/Genentech
 
Scott R. Solomon
No Relationships to Disclose
 
Ana Kostic
Employment - Bristol-Myers Squibb/Celgene/Juno
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene/Juno
 
Ashvin Singh
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Ricardo Espinola
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Rashmi Bhatnagar
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Anthony Raviele
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Michael Wang
Honoraria - Abbvie; Acerta Pharma; AstraZeneca; BeiGene; Bioinvent; Bristol Myers Squibb Foundation; CAHON; Catamount Medical Education; Dava Oncology; Genmab; Janssen Research & Development; Kite, a Gilead company; Merck; MSC National Research Institute of Oncology; NIH; Nurix; OncLive/MJH Life Sciences; Pharmacyclics/Janssen; Physicans' Education Resource; Research to Practice; Scripps Health; South African Clinical Hematology Society; Studio ER Congressi
Consulting or Advisory Role - Abbvie; Acerta Pharma; ADC Therapeutics; Amphista Therapeutics; AstraZeneca; BeiGene; Bioinvent; Deciphera; Genentech; Innocare; Janssen Research & Development; Kite, a Gilead company; Lilly; Merck; Miltenyi Biomedicine; Oncternal Therapeutics; Parexel; Pepromene; Pepromene; Pharmacyclics/Janssen; VelosBio
Research Funding - Acerta Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Bioinvent (Inst); Celgene (Inst); Genentech (Inst); Genmab (Inst); Innocare (Inst); Janssen Research & Development (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); Lilly (Inst); Loxo (Inst); Molecular Templates (Inst); Oncternal Therapeutics (Inst); Pharmacyclics (Inst); VelosBio (Inst); Vincerx Pharma (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Dava Oncology; Kite, a Gilead company; Physicans' Education Resource